Tanespimycin (17-AAG)

For research use only.

Catalog No.S1141 Synonyms: CP127374,NSC-330507, KOS 953

81 publications

Tanespimycin (17-AAG) Chemical Structure

CAS No. 75747-14-7

Tanespimycin (17-AAG, CP127374, NSC-330507, KOS 953) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Tanespimycin (17-AAG) induces apoptosis, necrosis, autophagy and mitophagy. Phase 3.

Size Price Stock Quantity  
10mM (1mL in DMSO) RMB 2350.91 In stock
RMB 795.18 In stock
RMB 2432.97 In stock
RMB 6527.43 In stock
RMB 10950.03 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Tanespimycin (17-AAG) has been cited by 81 publications

Purity & Quality Control

Choose Selective HSP (HSP90) Inhibitors

Biological Activity

Description Tanespimycin (17-AAG, CP127374, NSC-330507, KOS 953) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Tanespimycin (17-AAG) induces apoptosis, necrosis, autophagy and mitophagy. Phase 3.
Features Displays very low toxicity toward normal cells.
Targets
HSP90 [1]
(Cell-free assay)
5 nM
In vitro

17-AAG, an analog of geldanamycin, exhibits greater than 100 times higher binding affinity for Hsp90 derived from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells with IC50 values of 5-6 nM. [1] 17-AAG causes the degradation of HER2, HER3, Akt, and both mutant and wild-type androgen receptor (AR), leading to the RB-dependent G1 growth arrest of prostate cancer cells such as LNCaP, LAPC-4, DU-145, and PC-3 with IC50 values of 25-45 nM. [2] In addition to inducing apoptosis of Ba/F3 cells transformed with wild-type BCR-ABL with an IC50 of 5.2 μM, 17-AAG has the ability to induce apoptosis of cells transformed with imatinib mesylate-resistant T315I and E255K BCR-ABL mutants with IC50 values of 2.3 μM and 1.0 μM, respectively, by inducing the degradation of both wild-type BCR-ABL protein and mutants. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 MlvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rMZ2lEPTB;MD6wNFA{ODNizszN NHfKNZdUSU6JRWK=
IST-MEL1 NYjyZYxHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LLWmlEPTB;MD6wNFA1ODdizszN NXXq[mhpW0GQR1XS
NCI-SNU-1 NIrKWo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTBwMECyNFch|ryP MVvTRW5ITVJ?
FADU NIPOS4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTBwMECyNFkh|ryP MVfTRW5ITVJ?
C32 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrCTWM2OD1yLkCwN|A1KM7:TR?= Ml3vV2FPT0WU
D-566MG NWq1O|dQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXiTWM2OD1yLkCwN|kh|ryP MVXTRW5ITVJ?
LXF-289 NYPobXVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7jR49KSzVyPUCuNFA1OTlizszN NWjROXZnW0GQR1XS
HGC-27 MoX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTBwMEC1NUDPxE1? MVTTRW5ITVJ?
RPMI-7951 NHnUNHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzHfIdKSzVyPUCuNFA4OTdizszN NG\DTJpUSU6JRWK=
HSC-3 NVLndIRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHIUZFoUUN3ME2wMlAxQTJ7IN88US=> MVHTRW5ITVJ?
MIA-PaCa-2 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;MeGlEPTB;MD6wNVAxQSEQvF2= Ml7BV2FPT0WU
KS-1 NULI[mR2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rCVmlEPTB;MD6wNVM2PSEQvF2= Mn;0V2FPT0WU
CAL-51 M1PxSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTSR|c{UUN3ME2wMlAyPDB3IN88US=> M2XiRXNCVkeHUh?=
MDA-MB-361 NULMZXVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXHdIJKUUN3ME2wMlAyPDl3IN88US=> M1Pt[3NCVkeHUh?=
TI-73 Mn3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTBwMEG3PVYh|ryP MVnTRW5ITVJ?
AGS MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTBwMEG5N|gh|ryP M17UUnNCVkeHUh?=
NCI-H460 Moe5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fnTmlEPTB;MD6wNVk4PCEQvF2= MYnTRW5ITVJ?
A204 M{jCSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13UeGlEPTB;MD6wNlI1QSEQvF2= NW[1RmRLW0GQR1XS
CHL-1 NI\IbGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnrTWM2OD1yLkCyNlUyKM7:TR?= Mle4V2FPT0WU
DU-4475 MlLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGKzWXJKSzVyPUCuNFIzPjFizszN NFnSdY5USU6JRWK=
CGTH-W-1 NH3jZmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTBwMEKzOFkh|ryP MXzTRW5ITVJ?
HCC2218 NVHvXWZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LPZWlEPTB;MD6wNlQ6PCEQvF2= MlvaV2FPT0WU
A2780 MnnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTBwMEK1N|Eh|ryP NV70TmwzW0GQR1XS
NCI-H720 MlzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX6yU2V6UUN3ME2wMlAzPTR4IN88US=> M13lb3NCVkeHUh?=
NCI-N87 NH36dopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGW4VJJKSzVyPUCuNFI2QTNizszN MkmwV2FPT0WU
CHP-212 M1LFVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTBwMEK2Nlgh|ryP MmPaV2FPT0WU
NCI-H23 MkLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH60SFdKSzVyPUCuNFI3PjVizszN NWfydXV2W0GQR1XS
D-263MG MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1y5VWlEPTB;MD6wNlc5PiEQvF2= M2DsWHNCVkeHUh?=
ME-180 NIHHfFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7uTGdKSzVyPUCuNFI5QTFizszN NETDS3FUSU6JRWK=
SW982 M16zV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV2xfYtQUUN3ME2wMlAzQTl7IN88US=> MVTTRW5ITVJ?
OE19 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHPPVlKSzVyPUCuNFMxPzdizszN MlPtV2FPT0WU
SK-LU-1 NIPYZW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljsTWM2OD1yLkCzNFgzKM7:TR?= MlfVV2FPT0WU
H4 MliwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDQcHVKSzVyPUCuNFMxQSEQvF2= MmrhV2FPT0WU
HT-144 M2L6eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTBwMEOwPVMh|ryP NH6wTYRUSU6JRWK=
SK-UT-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\YcHlYUUN3ME2wMlA{OTd6IN88US=> NYqwcZFpW0GQR1XS
D-336MG NUjh[mxiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHpTWM2OD1yLkCzN|A6KM7:TR?= NEHJO5ZUSU6JRWK=
MDA-MB-175-VII NFXPc4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrVPZRKSzVyPUCuNFM{PTRizszN MU\TRW5ITVJ?
GAMG MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\6RXE4UUN3ME2wMlA{PDN3IN88US=> NFvqTYVUSU6JRWK=
CP50-MEL-B M{Dlcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{O1cWlEPTB;MD6wN|Q2KM7:TR?= NVXBcpNMW0GQR1XS
OVCAR-5 M4P5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFT5bY9KSzVyPUCuNFM1QCEQvF2= M{i1WnNCVkeHUh?=
SK-MES-1 M3Lp[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTBwMEO2NFYh|ryP M{O4O3NCVkeHUh?=
VM-CUB-1 M3jNWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX61WVM5UUN3ME2wMlA{PjV5IN88US=> MXHTRW5ITVJ?
WM-115 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnYWWZmUUN3ME2wMlA{PzZ{IN88US=> NHW4TZJUSU6JRWK=
DSH1 NXSxc5J3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWj0b3lyUUN3ME2wMlA{QDB5IN88US=> MlXsV2FPT0WU
Becker NFLVeHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTBwMEO4PFUh|ryP Mk\tV2FPT0WU
SW962 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnZUmxKSzVyPUCuNFM6PDVizszN NXLMd5NxW0GQR1XS
TYK-nu M{DHNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTBwMEO5PFUh|ryP NWTNdWVmW0GQR1XS
HO-1-N-1 MkXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILMSmZKSzVyPUCuNFQxOjFizszN NHXXcHpUSU6JRWK=
T98G NHj0eJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLqU49KSzVyPUCuNFQyODNizszN M{LBWXNCVkeHUh?=
ACN NF21NVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHuV49OUUN3ME2wMlA1OTZ{IN88US=> NG[wcHpUSU6JRWK=
SW780 NFvwW3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILTXGVKSzVyPUCuNFQzODNizszN MmX3V2FPT0WU
Detroit562 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zIeWlEPTB;MD6wOFI{QSEQvF2= MV3TRW5ITVJ?
BB49-HNC Mn3LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTBwMESyOFMh|ryP NG\x[INUSU6JRWK=
HN NU\IXGNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTBwMESyO|Ih|ryP MWLTRW5ITVJ?
H9 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fEXmlEPTB;MD6wOFM4OSEQvF2= Mo\YV2FPT0WU
VA-ES-BJ MnXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfWTWM2OD1yLkC0OFQ4KM7:TR?= NGLodlNUSU6JRWK=
MEL-JUSO NEjXOG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfB[5dZUUN3ME2wMlA1PDd3IN88US=> Mlz3V2FPT0WU
BT-474 NFvacVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LwVWlEPTB;MD6wOFUh|ryP MXrTRW5ITVJ?
CaR-1 MlriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3flPWlEPTB;MD6wOFU1QSEQvF2= M4PV[HNCVkeHUh?=
PSN1 NWPxOYF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXETWM2OD1yLkC0OlA{KM7:TR?= NVe5O2M3W0GQR1XS
KYSE-510 M4DadWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILvPGtKSzVyPUCuNFQ3PDlizszN NGmyW25USU6JRWK=
KP-4 MmjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nFSWlEPTB;MD6wOFc2OyEQvF2= NUXSWHhRW0GQR1XS
KYSE-410 MlHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TxNGlEPTB;MD6wOFc4OiEQvF2= MoPTV2FPT0WU
G-402 M{fTZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkGxTWM2OD1yLkC0O|g6KM7:TR?= NUnxblZNW0GQR1XS
DOK M3vHVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTBwMES5NFIh|ryP M4fWZnNCVkeHUh?=
COR-L88 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjIe5p[UUN3ME2wMlA1QTF{IN88US=> MoPLV2FPT0WU
SKG-IIIa MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzRTWM2OD1yLkC0PVg3KM7:TR?= MnH6V2FPT0WU
AN3-CA NG[z[5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTBwMEWg{txO MnLBV2FPT0WU
SW48 M4fPUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{C5WWlEPTB;MD6wOVA{QSEQvF2= M2T4OXNCVkeHUh?=
YKG-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnvTWM2OD1yLkC1NFcyKM7:TR?= NYLhb4l6W0GQR1XS
KYSE-150 MkXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPBTndKSzVyPUCuNFUzOzVizszN MVXTRW5ITVJ?
HuO-3N1 NELUVm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3[5[mlEPTB;MD6wOVI{PyEQvF2= NIfy[XBUSU6JRWK=
LB1047-RCC M1[0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTSfZpKSzVyPUCuNFUzQTZizszN NUDpenFvW0GQR1XS
NCI-H2030 NYnJeYpjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXWSW1KSzVyPUCuNFU1OTRizszN NHHKO5RUSU6JRWK=
YH-13 NHi0bZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPWeYV7UUN3ME2wMlA2PzJ{IN88US=> MkjjV2FPT0WU
5637 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLXTYQ{UUN3ME2wMlA2PzRizszN NULTRW9VW0GQR1XS
LOXIMVI MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTBwMEW4O|Ih|ryP MnHBV2FPT0WU
GT3TKB NFzGN4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHGTWM2OD1yLkC1PVQzKM7:TR?= Mn\2V2FPT0WU
TCCSUP M4\0[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLmSZpKSzVyPUCuNFU6PjRizszN M{TjWXNCVkeHUh?=
EPLC-272H Mlj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3G5RmlEPTB;MD6wOlIxPSEQvF2= NXfrcm1DW0GQR1XS
LU-99A MmnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDXTWM2OD1yLkC2NlM4KM7:TR?= NUf4[Vl4W0GQR1XS
NCI-H1755 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjrTWpKSzVyPUCuNFY{PDFizszN M3uzWXNCVkeHUh?=
KM12 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7OTWM2OD1yLkC2N|Q5KM7:TR?= Mmj3V2FPT0WU
SF295 M2TBd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTBwME[0OVIh|ryP NGTnOVFUSU6JRWK=
MZ2-MEL M2rSTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrXOHJKSzVyPUCuNFY2PTNizszN MVnTRW5ITVJ?
HEC-1 Ml;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn[0TWM2OD1yLkC2OVg5KM7:TR?= NGLkbpZUSU6JRWK=
SW684 NEf4UHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYP1WlVHUUN3ME2wMlA3PTlzIN88US=> NHW4NoJUSU6JRWK=
SF539 NIHTRpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDI[YtqUUN3ME2wMlA3PjhzIN88US=> NFnNUmNUSU6JRWK=
GMS-10 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFu4fWJKSzVyPUCuNFY3QTlizszN M2HNRXNCVkeHUh?=
MV-4-11 M2XaV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnkOndWUUN3ME2wMlA3QDB|IN88US=> MYPTRW5ITVJ?
HT-29 MnTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDs[25uUUN3ME2wMlA3QTF7IN88US=> MmnDV2FPT0WU
23132-87 NYnWT4NoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\B[JRnUUN3ME2wMlA3QTVizszN MUnTRW5ITVJ?
SW620 Mm\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYqxUHR3UUN3ME2wMlA4ODJ4IN88US=> NVzqUIRQW0GQR1XS
HCC1806 MoTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDqU3VFUUN3ME2wMlA4OTNzIN88US=> NVy5W5NVW0GQR1XS
Hs-578-T NWnifYU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7MTWM2OD1yLkC3NlA5KM7:TR?= M37MTXNCVkeHUh?=
A2058 NVTlfHV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTBwMEeyNlgh|ryP MWnTRW5ITVJ?
MEL-HO MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mne2TWM2OD1yLkC3NlU2KM7:TR?= MmX0V2FPT0WU
HCC2998 NHjPR3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrjT4tKSzVyPUCuNFc{PDdizszN MUXTRW5ITVJ?
HuO9 MlnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTlTWM2OD1yLkC3OVg6KM7:TR?= MnP6V2FPT0WU
CAL-39 MkfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmOzTWM2OD1yLkC3O|Y3KM7:TR?= MoXnV2FPT0WU
M14 M1\FbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTxcHZKSzVyPUCuNFc6OTNizszN NVPv[YJUW0GQR1XS
BFTC-909 NYnOS2YzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfoemtKSzVyPUCuNFc6PjlizszN MnW3V2FPT0WU
TE-11 MlX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTBwMEe5PVYh|ryP NGHTcGZUSU6JRWK=
TGBC1TKB M1:yemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfFbmlrUUN3ME2wMlA5ODR|IN88US=> NHvhSXpUSU6JRWK=
L-363 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTBwMEiyNFYh|ryP NFfNeXdUSU6JRWK=
A431 Mn;WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWq1b41jUUN3ME2wMlA5OjFizszN NVfrZXlbW0GQR1XS
MKN45 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojRTWM2OD1yLkC4NlE6KM7:TR?= MYHTRW5ITVJ?
HT-1080 NVP1TnNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnf1TWM2OD1yLkC4OFM6KM7:TR?= MXXTRW5ITVJ?
OVCAR-8 M3\tcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\JTWM2OD1yLkC4OlIzKM7:TR?= NITlbo5USU6JRWK=
LCLC-97TM1 M4LSWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjaTWM2OD1yLkC4O|I5KM7:TR?= NYDRPJpyW0GQR1XS
M059J NF3jZ2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDGTWM2OD1yLkC5NFI4KM7:TR?= M3zxXnNCVkeHUh?=
SK-MEL-2 M1LLSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnroTWM2OD1yLkC5NFYh|ryP NHrvZ4ZUSU6JRWK=
TE-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HlZWlEPTB;MD6wPVIxPCEQvF2= MnHQV2FPT0WU
KYSE-180 M4DLWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPJN29KSzVyPUCuNFkzPjJizszN NV\4NIRVW0GQR1XS
D-247MG MoPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPiNFNJUUN3ME2wMlA6PDV3IN88US=> MoXJV2FPT0WU
8-MG-BA MmXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTrPYhCUUN3ME2wMlA6PDd{IN88US=> M3;zdHNCVkeHUh?=
NCI-H1792 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIToOXlKSzVyPUCuNFk3OThizszN NGPPN4pUSU6JRWK=
MCF7 NXTlWoNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jNT2lEPTB;MD6wPVY4PyEQvF2= MmDaV2FPT0WU
NCI-H2122 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfJTWM2OD1yLkC5O|Q2KM7:TR?= M{DoPXNCVkeHUh?=
EFO-27 NHO2XJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{X5XmlEPTB;MD6wPVk6PyEQvF2= NUfLcmNqW0GQR1XS
LB2241-RCC M3PBeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTlTWM2OD1yLkGwNFU1KM7:TR?= NUnRb4ZrW0GQR1XS
SN12C M325TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUC0dWVOUUN3ME2wMlExOTB5IN88US=> M3[2ZXNCVkeHUh?=
A498 M1jrVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPONZBTUUN3ME2wMlExOThizszN MVLTRW5ITVJ?
PANC-03-27 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDQTWM2OD1yLkGwNlg3KM7:TR?= MofwV2FPT0WU
NCI-H1581 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\FfWlEPTB;MD6xNFI6KM7:TR?= NIHJRWZUSU6JRWK=
U-87-MG NVu3PXEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4S3eGlEPTB;MD6xNFMxPyEQvF2= NGnGVVhUSU6JRWK=
G-401 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nRNWlEPTB;MD6xNFM2OyEQvF2= M{DPNXNCVkeHUh?=
SiHa M1K3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXu1WWtCUUN3ME2wMlExPDh4IN88US=> M2L4fnNCVkeHUh?=
U251 M2LRRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTBwMUC1NlUh|ryP MVnTRW5ITVJ?
MMAC-SF NUDBOpIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rTcmlEPTB;MD6xNFU{OSEQvF2= MYDTRW5ITVJ?
BB65-RCC NViwXmI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUT4Z5dvUUN3ME2wMlExPTV2IN88US=> MlrWV2FPT0WU
NKM-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnQS5M1UUN3ME2wMlExPjZ4IN88US=> NGPMfpVUSU6JRWK=
HD-MY-Z Mm\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTxdVlKSzVyPUCuNVA5PzNizszN M4PUNnNCVkeHUh?=
TGBC11TKB NGfWemdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTBwMUC5NFMh|ryP NEjlbIRUSU6JRWK=
COLO-679 NVzVbGtKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYe1PFJ5UUN3ME2wMlEyOjFzIN88US=> MWXTRW5ITVJ?
TE-8 NVOyS2RkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTBwMUGyOlQh|ryP Mki2V2FPT0WU
SK-MEL-28 NVnvUGdWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\VcGhKSzVyPUCuNVE{OjFizszN NILQSJpUSU6JRWK=
SH-4 M4Oye2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3hNGJKSzVyPUCuNVE{PTZizszN MmqyV2FPT0WU
KALS-1 M4n3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGO2OIVKSzVyPUCuNVE{QTNizszN MX\TRW5ITVJ?
RKO Mn\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLSTWM2OD1yLkGxO|Y1KM7:TR?= NGTyfI1USU6JRWK=
OMC-1 MljFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTBwMUG3PVch|ryP NI\BRWhUSU6JRWK=
BT-549 NF7GTWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jKfmlEPTB;MD6xNVc6QSEQvF2= MX;TRW5ITVJ?
NCI-H28 NETqNIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M36zXWlEPTB;MD6xNVgyPyEQvF2= MofQV2FPT0WU
RXF393 NGCwe|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETuVHpKSzVyPUCuNVE6QDJizszN NHPzZ29USU6JRWK=
COLO-829 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnzb2RmUUN3ME2wMlEzODB3IN88US=> MXHTRW5ITVJ?
HMV-II MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH[xZ5RKSzVyPUCuNVIxOiEQvF2= NGi2NYVUSU6JRWK=
SW1990 NUTRR29bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HMTmlEPTB;MD6xNlE2PyEQvF2= NHjRc5VUSU6JRWK=
NCI-H1437 NYPtSY5iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\aTpluUUN3ME2wMlEzOTV5IN88US=> MoqxV2FPT0WU
SNB75 M37tPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTUTWM2OD1yLkGyNVY6KM7:TR?= MmOyV2FPT0WU
EW-3 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13vRWlEPTB;MD6xNlY3OSEQvF2= MWfTRW5ITVJ?
SAS MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTBwMUK2PUDPxE1? NYPyb4tzW0GQR1XS
NCI-H1666 M2qyTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELnO4VKSzVyPUCuNVI4PzRizszN M4nyXnNCVkeHUh?=
A375 MkDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXHTWM2OD1yLkGyO|c5KM7:TR?= MlvOV2FPT0WU
CAMA-1 M1LJe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn2wTWM2OD1yLkGyPVI1KM7:TR?= NUDOU5R2W0GQR1XS
HuP-T4 M2\WTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnBUYVKSzVyPUCuNVI6PDNizszN MV7TRW5ITVJ?
NCI-H292 MorkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHOPHJKSzVyPUCuNVMyOSEQvF2= NH;UUFhUSU6JRWK=
PC-14 NFeyNVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHFdXdtUUN3ME2wMlE{OjFzIN88US=> MWjTRW5ITVJ?
BPH-1 MnXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXC[JdlUUN3ME2wMlE{PDFizszN M2LCbXNCVkeHUh?=
GAK MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjsToNKSzVyPUCuNVM2PjdizszN NFHjNmtUSU6JRWK=
VMRC-RCZ Mnf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\6dmlEPTB;MD6xN|c3OiEQvF2= M3S3WXNCVkeHUh?=
SK-MEL-24 NYX3PWxNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTBwMUO4O{DPxE1? NF3vdGVUSU6JRWK=
LB831-BLC NVzEOZlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3VNYZKSzVyPUCuNVM5QDNizszN NIjBN4NUSU6JRWK=
NCI-H2452 MljCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTBwMUO5OVYh|ryP NYjteXE5W0GQR1XS
RT-112 NX64[WU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPqRY5rUUN3ME2wMlE1ODN3IN88US=> M4DzcXNCVkeHUh?=
GP5d NIXCfZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnEeFZKSzVyPUCuNVQyODRizszN NH;kXlJUSU6JRWK=
LC-2-ad MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPyeWJTUUN3ME2wMlE1OTJzIN88US=> M3PDc3NCVkeHUh?=
MPP-89 NI\CUFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnSzTWM2OD1yLkG0NVI2KM7:TR?= NID4N3BUSU6JRWK=
NUGC-3 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDTTWM2OD1yLkG0OFc5KM7:TR?= MVPTRW5ITVJ?
GI-1 NYjaeJVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlS0TWM2OD1yLkG0OVU5KM7:TR?= NEjTTYFUSU6JRWK=
HCC1419 MorWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUj4e|k5UUN3ME2wMlE1PTd4IN88US=> Mlf2V2FPT0WU
SW1573 NIW2WINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mme0TWM2OD1yLkG0O|U5KM7:TR?= M3;ub3NCVkeHUh?=
NCI-H2347 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfKTWM2OD1yLkG0PFM6KM7:TR?= NXj1bWZxW0GQR1XS
Mewo MkPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVviUHA2UUN3ME2wMlE1QDh7IN88US=> M2PxXHNCVkeHUh?=
639-V M{TyT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTBwMUWwNVMh|ryP NUC4[XloW0GQR1XS
AsPC-1 NYHBWYM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HsXmlEPTB;MD6xOVIzPSEQvF2= NWrSR4N2W0GQR1XS
NCI-H1648 MkLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFuwPYdKSzVyPUCuNVUzOzJizszN NG\oe3VUSU6JRWK=
786-0 NG\qS2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTBwMUWzPFEh|ryP NXyyXmlzW0GQR1XS
ETK-1 NIPKc5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELXTJpKSzVyPUCuNVU6KM7:TR?= MUnTRW5ITVJ?
BxPC-3 NUHpWW9YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NViyWJZZUUN3ME2wMlE2QTZ4IN88US=> MkS5V2FPT0WU
CAL-62 MnfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mon0TWM2OD1yLkG2NVY6KM7:TR?= NUPKelhmW0GQR1XS
HCC1937 NV36[XJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfIWZpKSzVyPUCuNVYzPzVizszN NVzLSHhlW0GQR1XS
NCI-H1299 NUjkToRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XP[mlEPTB;MD6xOlI5PSEQvF2= Ml3OV2FPT0WU
SW1088 NY[5doRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGO0NlhKSzVyPUCuNVY1OTNizszN NXHP[pFmW0GQR1XS
FTC-133 NYC0c5F5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTBwMU[1OEDPxE1? NWDMRVRzW0GQR1XS
OC-314 M1rCNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3NTWM2OD1yLkG2Olkh|ryP NXTNPJE4W0GQR1XS
SCC-9 M{jYT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTzdpRnUUN3ME2wMlE3PzF4IN88US=> M3rydHNCVkeHUh?=
HT-1376 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3BWotKSzVyPUCuNVY6OzZizszN MYDTRW5ITVJ?
U-2-OS NGP0b4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvQTWM2OD1yLkG3NVc{KM7:TR?= M2f0ZXNCVkeHUh?=
COLO-824 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jGOWlEPTB;MD6xO|I6PCEQvF2= M2PWfnNCVkeHUh?=
BB30-HNC NIH4XoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jpcmlEPTB;MD6xO|M{KM7:TR?= NITCcYZUSU6JRWK=
NCI-H2087 MlzSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLqTWM2OD1yLkG3N|Y5KM7:TR?= MXvTRW5ITVJ?
NCI-H2170 MlfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTBwMUe1N|Yh|ryP MXfTRW5ITVJ?
SK-OV-3 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrLcYxKSzVyPUCuNVc2PzFizszN NX\XV|VxW0GQR1XS
MZ7-mel M3HaOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjZR3VKSzVyPUCuNVc3PDlizszN M4[0OnNCVkeHUh?=
NCI-H650 MojvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfPTmY4UUN3ME2wMlE4Pjh{IN88US=> NYrENmJDW0GQR1XS
KOSC-2 MknyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LDb2lEPTB;MD6xO|c{PCEQvF2= NYnuWlF4W0GQR1XS
SCC-4 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NET1dYRKSzVyPUCuNVc4PzdizszN M3npdnNCVkeHUh?=
MDA-MB-157 NULwWIJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fzVGlEPTB;MD6xPFA5OiEQvF2= NUTydGEzW0GQR1XS
KYSE-520 NGDMUmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjWb2h5UUN3ME2wMlE5OiEQvF2= NUDPUJc1W0GQR1XS
LK-2 NV3PeGZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\PeWlEPTB;MD6xPFMxOyEQvF2= MmH5V2FPT0WU
KNS-81-FD Mn;QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjWOIJKSzVyPUCuNVg{QTRizszN NWW0TG5SW0GQR1XS
IGROV-1 NUP1bFI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjKTWM2OD1yLkG4OFQ{KM7:TR?= M1i0enNCVkeHUh?=
DEL NYS0cJI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfKTJdKSzVyPUCuNVg1PSEQvF2= NHfXeVBUSU6JRWK=
NCI-H1395 NGDtSWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3HTWM2OD1yLkG4OlgzKM7:TR?= NGr5cJVUSU6JRWK=
JEG-3 NXGwOIxxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjnTWM2OD1yLkG4O|A2KM7:TR?= NXiwVFhtW0GQR1XS
BCPAP NVTKcI9PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TLNmlEPTB;MD6xPFg4OiEQvF2= NEDFdYhUSU6JRWK=
CAL-27 NWX6eYk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17udGlEPTB;MD6xPVAzOiEQvF2= MlfXV2FPT0WU
RD MoO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTBwMUmxNVMh|ryP NIiwWoFUSU6JRWK=
RVH-421 MkTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17wN2lEPTB;MD6xPVEyPiEQvF2= NUX2dGpPW0GQR1XS
Capan-2 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTBwMUmyOVYh|ryP NW\od5FWW0GQR1XS
COLO-680N M3v2WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTBwMUmzOlQh|ryP MYHTRW5ITVJ?
NCI-H1650 Mk\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jZXWlEPTB;MD6yNFA2PyEQvF2= MVnTRW5ITVJ?
SBC-5 MnzES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;CTWM2OD1yLkKwNVE5KM7:TR?= NY\5d|JvW0GQR1XS
U031 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVP1[YVqUUN3ME2wMlIxPTR5IN88US=> NWHGWo1pW0GQR1XS
S-117 Mk\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGD6XIxKSzVyPUCuNlA2PjRizszN NGHmPGlUSU6JRWK=
DoTc2-4510 MnztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTBwMkC3Olkh|ryP NUTyPZdnW0GQR1XS
AM-38 MlXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DNSWlEPTB;MD6yNFg1QCEQvF2= MXvTRW5ITVJ?
A172 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvWVYhKSzVyPUCuNlExOjJizszN MmrtV2FPT0WU
HPAF-II NWPsSZJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLKfWhKSzVyPUCuNlEzPjRizszN NVfzb5VEW0GQR1XS
769-P M3PwXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vkSmlEPTB;MD6yNVI5KM7:TR?= MnLuV2FPT0WU
MFE-280 M2\rS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rMemlEPTB;MD6yNVI6QCEQvF2= MXjTRW5ITVJ?
TE-9 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTBwMkG3PFYh|ryP MkW0V2FPT0WU
C2BBe1 NFfWeXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLUTWM2OD1yLkKyNVkh|ryP MkXzV2FPT0WU
EoL-1-cell NEG3RmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTBwMkKyNFMh|ryP M3fUTHNCVkeHUh?=
G-361 NWPqUIFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLJTWM2OD1yLkKyOlgzKM7:TR?= NI[zUWhUSU6JRWK=
KYSE-270 M3LzWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTBwMkOwPFQh|ryP NILsSIVUSU6JRWK=
TK10 NV2xSJI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3npOmlEPTB;MD6yN|EyPyEQvF2= MUjTRW5ITVJ?
ML-2 NEXEeGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4Dm[GlEPTB;MD6yN|EyQSEQvF2= MV7TRW5ITVJ?
MHH-ES-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTBwMkO2PFEh|ryP Mn3EV2FPT0WU
BHY NFnVZ2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGS0XnBKSzVyPUCuNlM3QTFizszN NGjuenpUSU6JRWK=
LS-513 MkPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTBwMkO5OlEh|ryP M4PkVXNCVkeHUh?=
COLO-678 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33KeWlEPTB;MD6yOFA1PCEQvF2= MWjTRW5ITVJ?
NCI-H747 MlOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\ieWVPUUN3ME2wMlI1OTZ7IN88US=> NFfHeIZUSU6JRWK=
K5 NGmydpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoixTWM2OD1yLkK0N|gh|ryP NYe2fndmW0GQR1XS
OS-RC-2 NVjKOZp[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PZeGlEPTB;MD6yOFUxQSEQvF2= MlziV2FPT0WU
KINGS-1 Ml7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\5XHBZUUN3ME2wMlI1PTJ7IN88US=> Mo\zV2FPT0WU
SCC-25 Ml7TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fRRWlEPTB;MD6yOFU3OyEQvF2= NIjBcpJUSU6JRWK=
CAPAN-1 NGfUSoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTBwMkS3PFMh|ryP M1LTVHNCVkeHUh?=
ESS-1 MoW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjIUFNDUUN3ME2wMlI1QDB3IN88US=> NHfWOVBUSU6JRWK=
TE-6 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TrVmlEPTB;MD6yOVc2KM7:TR?= MnnwV2FPT0WU
LB2518-MEL NH3ISlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTBwMkW3O|ch|ryP NGXNUGlUSU6JRWK=
COLO-800 MkX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjXOGRiUUN3ME2wMlI2QDF{IN88US=> M3vwSHNCVkeHUh?=
LU-134-A M2nQSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTBwMk[xN|Yh|ryP MmHyV2FPT0WU
NCI-H1155 M1zuVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfl[3BKSzVyPUCuNlYyPjJizszN NVLPd3FVW0GQR1XS
MFM-223 MlvtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{f1d2lEPTB;MD6yOlM3OyEQvF2= M4PRdHNCVkeHUh?=
HTC-C3 NGDYZpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfxTWNKSzVyPUCuNlY2ODZizszN NVzYNVJTW0GQR1XS
HCT-116 NU\xToJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvE[WJKSzVyPUCuNlY2QTlizszN MYLTRW5ITVJ?
Ca-Ski MkPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrnR2dKSzVyPUCuNlY3PzhizszN MmnBV2FPT0WU
SBC-1 NXz3S2s4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVS5[ndPUUN3ME2wMlI3PzR{IN88US=> NYrTcJAyW0GQR1XS
NB69 NIrBfZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHGwR3pKSzVyPUCuNlcxQDdizszN Mn7jV2FPT0WU
J82 NUG2NWlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorBTWM2OD1yLkK3NlY2KM7:TR?= NIDyZoVUSU6JRWK=
U-118-MG MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnP5TWM2OD1yLkK3OVc6KM7:TR?= MmW5V2FPT0WU
NCI-H1355 NHjPVVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrmTWM2OD1yLkK4NFc1KM7:TR?= NGGwXllUSU6JRWK=
NCI-H1048 Ml65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjRTWM2OD1yLkK4PVU3KM7:TR?= M4\EV3NCVkeHUh?=
SW954 M4DZ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTBwMkmyNlch|ryP NFrwfpZUSU6JRWK=
NMC-G1 NIjhbmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUP4SWExUUN3ME2wMlI6Ojd5IN88US=> MlT2V2FPT0WU
SW1710 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\NTnJlUUN3ME2wMlI6PDl2IN88US=> MV3TRW5ITVJ?
KY821 NWHlVIFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3iTWM2OD1yLkK5PFczKM7:TR?= MYPTRW5ITVJ?
HCC38 NWDxc244T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HwXGlEPTB;MD6zNFA4QCEQvF2= NVj2WYYzW0GQR1XS
NCI-SNU-5 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzZZnRMUUN3ME2wMlMxPTRizszN NHLzXGVUSU6JRWK=
ES8 M{HGfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTBwM{C3PFQh|ryP NH3ZcFBUSU6JRWK=
COLO-792 NEO1[mRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTBwM{GyOVEh|ryP MUnTRW5ITVJ?
BFTC-905 NUHERnJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHf6d5hKSzVyPUCuN|E2OjFizszN M1jXNnNCVkeHUh?=
ChaGo-K-1 NIDMd49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3H0RWlEPTB;MD6zNVcyPSEQvF2= NVfQUGpKW0GQR1XS
Daoy NX;DfIRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTBwM{G3NlMh|ryP M2ToRXNCVkeHUh?=
SJSA-1 NXS4THo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{m3S2lEPTB;MD6zNVg1PyEQvF2= NHnuU3ZUSU6JRWK=
KNS-62 NEDSPGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmntTWM2OD1yLkOyNFg5KM7:TR?= MVTTRW5ITVJ?
CAKI-1 NVLYTGFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTBwM{KxNVEh|ryP M4PlNXNCVkeHUh?=
UACC-62 MlPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTBwM{KyNlch|ryP NHjL[YNUSU6JRWK=
HuCCT1 M2PufWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfRNpZtUUN3ME2wMlMzOjh|IN88US=> MVHTRW5ITVJ?
CTB-1 MnHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkX2TWM2OD1yLkOyO|U{KM7:TR?= MYTTRW5ITVJ?
NTERA-S-cl-D1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TXSGlEPTB;MD6zNlg{PiEQvF2= NXHmPYZ7W0GQR1XS
T-24 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvBRYpKSzVyPUCuN|MyPTlizszN NHzWe2hUSU6JRWK=
KYSE-70 NXrZXWh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TtcGlEPTB;MD6zN|I5OyEQvF2= Moq4V2FPT0WU
SW626 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XFOGlEPTB;MD6zN|U{OiEQvF2= NIfkTJpUSU6JRWK=
LB996-RCC MkPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTBwM{O2NVkh|ryP M4foXHNCVkeHUh?=
DMS-273 MoK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;CeWlEPTB;MD6zN|kyPiEQvF2= M17rdnNCVkeHUh?=
SW1783 NVjFVohoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTBwM{O5PVch|ryP MVvTRW5ITVJ?
KU812 Mmm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3MVJROUUN3ME2wMlM1ODN6IN88US=> M4DoeHNCVkeHUh?=
HSC-2 NH3jVXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIL2TohKSzVyPUCuN|QxPTNizszN M4X2SXNCVkeHUh?=
A3-KAW M4Lw[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzIb5JIUUN3ME2wMlM1OTZ{IN88US=> M3T1PXNCVkeHUh?=
COLO-684 Ml7VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmT0TWM2OD1yLkO0OVAyKM7:TR?= M3rxZnNCVkeHUh?=
NCI-H2405 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLvZpRKSzVyPUCuN|Q3OzFizszN NFLnT25USU6JRWK=
NCI-H2228 MmPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrwZ2EyUUN3ME2wMlM2OzV5IN88US=> NX\nZo13W0GQR1XS
NB13 NIC3SY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGW1UZdKSzVyPUCuN|Y5OjlizszN M4TxXnNCVkeHUh?=
no-11 Mo\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLmSlVkUUN3ME2wMlM3QTVizszN MXzTRW5ITVJ?
DK-MG NIXq[WpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLFTWM2OD1yLkO3NVg5KM7:TR?= NUTnUWNTW0GQR1XS
NBsusSR NV\3[Jl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTBwM{eyPFUh|ryP MkTVV2FPT0WU
KP-N-YS M{\qV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHyeY96UUN3ME2wMlM4PDZ|IN88US=> NUDYd5BVW0GQR1XS
CFPAC-1 M{L3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\6VGlEPTB;MD6zO|UyQCEQvF2= MX;TRW5ITVJ?
KARPAS-45 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrNVVVKSzVyPUCuN|c5PjJizszN NXTsRoFiW0GQR1XS
NCI-H1793 NEjBU4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPGOpJGUUN3ME2wMlM5PTFizszN MnHxV2FPT0WU
HCE-T MkLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moi2TWM2OD1yLkO4OlA{KM7:TR?= NETaPHBUSU6JRWK=
NCI-H520 Mn3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{S1cGlEPTB;MD6zPFcxOyEQvF2= MlzPV2FPT0WU
HCC2157 M3G5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTBwM{i3PFEh|ryP MVLTRW5ITVJ?
EW-18 MmDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfQTWM2OD1yLkO4PVQyKM7:TR?= MoDSV2FPT0WU
RO82-W-1 NXf0R4lOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHyTWM2OD1yLkO5Olk6KM7:TR?= NG\IdHNUSU6JRWK=
HuP-T3 NF3lbIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPEW41KSzVyPUCuOFAyPDNizszN M{nuOHNCVkeHUh?=
PANC-10-05 NFznTFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnH4TWM2OD1yLkSxNVch|ryP M330SnNCVkeHUh?=
NCI-H1703 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTMTWM2OD1yLkSxOFQ3KM7:TR?= MojCV2FPT0WU
TE-10 M1jQSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLFTWM2OD1yLkSxOFQ4KM7:TR?= NX7tb2lxW0GQR1XS
HOS NHHyV2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITSWlZKSzVyPUCuOFE3QDJizszN M{X5SHNCVkeHUh?=
LN-405 MoTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTBwNEG2PFch|ryP MXHTRW5ITVJ?
A427 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPkVml2UUN3ME2wMlQyQThzIN88US=> NI\jOZBUSU6JRWK=
CAL-12T MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVL1dY5TUUN3ME2wMlQzPzhizszN M2PJfnNCVkeHUh?=
SW756 MkjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2WyXGlEPTB;MD60OFE5OyEQvF2= NXTab5ZjW0GQR1XS
YAPC NIiwfGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnrUYZPUUN3ME2wMlQ2ODhizszN NH\MOXVUSU6JRWK=
GOTO NIOxVoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4W1TmlEPTB;MD60OVE3KM7:TR?= MYfTRW5ITVJ?
C3A NFLKXIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfU[3AxUUN3ME2wMlQ2PDN5IN88US=> M{LBZXNCVkeHUh?=
UM-UC-3 M3nBVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTBwNEW0O{DPxE1? NXfqd4JQW0GQR1XS
NCI-H1573 M{naV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF64U5BKSzVyPUCuOFU2PjlizszN NH;0PJNUSU6JRWK=
LS-411N NVr5d2g{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLjO2dKSzVyPUCuOFY2OjdizszN Mom3V2FPT0WU
COR-L23 NX3YR4IxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFm4VJNKSzVyPUCuOFY4PjRizszN MVPTRW5ITVJ?
HCE-4 Mk\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTBwNEe0OFYh|ryP NFr6UGNUSU6JRWK=
NCI-H2291 NGjB[I9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4r5e2lEPTB;MD60O|g6PiEQvF2= NETZeZVUSU6JRWK=
A101D M3nqcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkK2TWM2OD1yLkS4NFU{KM7:TR?= NWT3bFR4W0GQR1XS
HT-3 NWX2N2RHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLTUlhWUUN3ME2wMlQ5OjF5IN88US=> MkHDV2FPT0WU
HOP-62 NIn4ZpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjwV|V2UUN3ME2wMlQ6QDZ3IN88US=> MVvTRW5ITVJ?
PC-3 NIHobolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2n5[WlEPTB;MD61NVUxPyEQvF2= MXrTRW5ITVJ?
CTV-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIm3bG1KSzVyPUCuOVI3PjlizszN NYWwXGdWW0GQR1XS
PANC-08-13 NHP6emJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjLdmtKSzVyPUCuOVMyPzdizszN NHf1cYtUSU6JRWK=
CAL-120 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTBwNUOzPVkh|ryP MVPTRW5ITVJ?
UMC-11 MkfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTBwNUWyN|Qh|ryP M4fsNHNCVkeHUh?=
MSTO-211H NXPoO4lnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TxWmlEPTB;MD61OVc3OiEQvF2= NYLUVVl2W0GQR1XS
NCI-H2126 M2DaZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFm3PHRKSzVyPUCuOVY5OTVizszN MWXTRW5ITVJ?
SNU-C2B M1WxUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnWTWM2OD1yLkW3PVc4KM7:TR?= M1mzenNCVkeHUh?=
DBTRG-05MG M{jmTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnn4TWM2OD1yLkW4NFU{KM7:TR?= M1rTW3NCVkeHUh?=
MKN1 NWG3VoJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXCSYM4UUN3ME2wMlU5Pzh|IN88US=> MVTTRW5ITVJ?
ES3 MkGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlq3TWM2OD1yLkW5NVI1KM7:TR?= NX7uR|VnW0GQR1XS
OVCAR-3 MnnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rxRWlEPTB;MD61PVM1OSEQvF2= MX\TRW5ITVJ?
ACHN NVj2XlFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHS2VlRKSzVyPUCuOlA2PjlizszN Mn;wV2FPT0WU
SW872 M1P5Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1r6V2lEPTB;MD62NFc3OyEQvF2= MXvTRW5ITVJ?
CP66-MEL NXT1VlVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTBwNkC5Olkh|ryP MnLWV2FPT0WU
NCI-H661 M4TzVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XYUGlEPTB;MD62NVExPCEQvF2= M4P4OnNCVkeHUh?=
UACC-893 NGTZeXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rGR2lEPTB;MD62N|Y5OSEQvF2= M1L5cXNCVkeHUh?=
JVM-3 NV3IelVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTBwNkO4NFQh|ryP MV3TRW5ITVJ?
SF268 NFO5eXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTBwNkSzOFkh|ryP M3naT3NCVkeHUh?=
OCI-AML2 M2\QW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jjc2lEPTB;MD62OVM6PyEQvF2= M2TEb3NCVkeHUh?=
RPMI-8226 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrVd3RKSzVyPUCuOlY{OjNizszN MUHTRW5ITVJ?
MKN28 Mm\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XnOmlEPTB;MD62OlYzPCEQvF2= NXzN[YdvW0GQR1XS
MDA-MB-453 MkfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M173bmlEPTB;MD62O|E5KM7:TR?= M2jwUHNCVkeHUh?=
BV-173 MmHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPrTWM2OD1yLk[4Olc6KM7:TR?= MoTHV2FPT0WU
NCI-H358 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTBwNki3NlYh|ryP M2rvfHNCVkeHUh?=
NCI-H1651 Ml\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jpb2lEPTB;MD63JO69VQ>? NVjSVINIW0GQR1XS
MDA-MB-415 Mnm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLWTWM2OD1yLkewPFI6KM7:TR?= M1iwXnNCVkeHUh?=
8305C NXj4NmZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTBwN{K0PVgh|ryP MYPTRW5ITVJ?
EFM-19 M3X1XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLFNotyUUN3ME2wMlc{PjdzIN88US=> NWm2VG9UW0GQR1XS
RERF-LC-MS MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHyRXBKUUN3ME2wMlc1PjF|IN88US=> MlPVV2FPT0WU
A388 NXLRWIp{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTBwN{[0Olch|ryP NY\QdXhJW0GQR1XS
GI-ME-N NIn5e5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoP3TWM2OD1yLke3NlM2KM7:TR?= Mm\6V2FPT0WU
IGR-1 NF:4[mRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHsfGxKSzVyPUCuO|kxPDNizszN M3vqXHNCVkeHUh?=
LNCaP-Clone-FGC Mki0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PkRmlEPTB;MD64NFAxPCEQvF2= NGTldGtUSU6JRWK=
SK-MEL-3 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{W1dWlEPTB;MD64NVUxQCEQvF2= NUn5c3d4W0GQR1XS
UACC-257 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTKUYhKSzVyPUCuPFIzOzFizszN M1HaOnNCVkeHUh?=
OE33 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTBwOEWxNFEh|ryP MknLV2FPT0WU
QIMR-WIL NFzVfHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTBwOEWxOFEh|ryP NWLrNIdVW0GQR1XS
NCI-H2009 NETSe4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHPTWM2OD1yLki1N|EyKM7:TR?= MlvsV2FPT0WU
NCI-H522 NIrXOYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEm2V|hKSzVyPUCuPFc4QDNizszN NH3wUVJUSU6JRWK=
Saos-2 M3G2UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{X3TWlEPTB;MD64O|g4OSEQvF2= MUjTRW5ITVJ?
NB17 Mmf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnm3TWM2OD1yLki4NFI2KM7:TR?= NUXuTZQ5W0GQR1XS
D-392MG NETM[o5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTBwOEmzOVYh|ryP MnTMV2FPT0WU
SHP-77 M335eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTBwOUC0PFUh|ryP MlvDV2FPT0WU
SK-MEL-30 NIHwPHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7sTWM2OD1yLkmxNVg2KM7:TR?= M4DKZnNCVkeHUh?=
GCIY M1nuVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTSTWM2OD1yLkmxPFQ{KM7:TR?= NUDUZ2FmW0GQR1XS
HCC70 NYPtSHJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTBwOUKwOVkh|ryP M{[wTHNCVkeHUh?=
LU-65 MlvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTBwOUK1PVEh|ryP MWfTRW5ITVJ?
NCI-H1563 Ml\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLTTWM2OD1yLkm0PFY2KM7:TR?= MlfQV2FPT0WU
KURAMOCHI NGjpNmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3VZ|BKSzVyPUCuPVUyQTJizszN M2XkR3NCVkeHUh?=
PA-1 NYfsW5U5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXu1cnU5UUN3ME2wMlk2PDJ2IN88US=> MXTTRW5ITVJ?
NOS-1 M1nGWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTKTWM2OD1yLkm3OFg6KM7:TR?= MX3TRW5ITVJ?
NCI-H69 Mmm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PtVmlEPTB;MD65O|Y{PCEQvF2= MkfwV2FPT0WU
KYSE-450 NELL[5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmn5TWM2OD1yLkm4OlI3KM7:TR?= Ml7IV2FPT0WU
8505C MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXRTWM2OD1yLkm5PVgzKM7:TR?= MnLvV2FPT0WU
TGBC24TKB NIrXR5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTFwMECwPFQh|ryP NIDWS5hUSU6JRWK=
PFSK-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TMV2lEPTB;MT6wNVQzQCEQvF2= NWLTOpFkW0GQR1XS
EKVX MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\pSGd3UUN3ME2xMlA{OTJzIN88US=> NH;tdIdUSU6JRWK=
RCM-1 MnXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorHTWM2OD1zLkC1OVA4KM7:TR?= MV;TRW5ITVJ?
SW900 MnXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\iOWlEPTB;MT6wO|g{KM7:TR?= NFX6fY1USU6JRWK=
D-542MG M{XJOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIX6VplKSzVyPUGuNFc5PTVizszN M3KxNHNCVkeHUh?=
SK-PN-DW MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mln1TWM2OD1zLkGwNFU3KM7:TR?= NHTBSnhUSU6JRWK=
NCI-H727 NVvlWHBYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPKR2xFUUN3ME2xMlExOTV2IN88US=> NVXhNm5rW0GQR1XS
SW837 NXHq[FQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XUXGlEPTB;MT6xNFk2PCEQvF2= MWHTRW5ITVJ?
BT-20 Moq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3ZbINzUUN3ME2xMlEyOjB2IN88US=> MXrTRW5ITVJ?
RH-18 MlPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rVTmlEPTB;MT6xN|ExOyEQvF2= MoSzV2FPT0WU
TE-12 NXf6VphDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DrT2lEPTB;MT6xN|M{OyEQvF2= NYTnRYQxW0GQR1XS
NB10 Mn3XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPBTWM2OD1zLkGzN|Q1KM7:TR?= MWrTRW5ITVJ?
AU565 NIHJNmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHpR2FKSzVyPUGuNVU6PzNizszN NYLIUo96W0GQR1XS
OAW-42 M{j4bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTFwMUizNFYh|ryP NX;DZZlCW0GQR1XS
DJM-1 M4XlXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnrfYlrUUN3ME2xMlE6QDhzIN88US=> M1fMUHNCVkeHUh?=
HH Ml7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\SdWlEPTB;MT6yN|g{OSEQvF2= MkDiV2FPT0WU
LAMA-84 NEe3RZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzDZ2hKSzVyPUGuNlc{QTRizszN MmnoV2FPT0WU
KNS-42 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\qWnZMUUN3ME2xMlMxOjl4IN88US=> NIfMPVBUSU6JRWK=
NCI-H2052 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHJZ4tKSzVyPUGuN|A2ODdizszN NVXqW3V2W0GQR1XS
MLMA MlP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTFwM{K0NFch|ryP MmD4V2FPT0WU
NB12 MljkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPSdmVKSzVyPUGuN|U3OzZizszN M4PuVnNCVkeHUh?=
NCI-H1838 MnTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTFwM{[zNFYh|ryP M{XDUHNCVkeHUh?=
NCI-H526 MoLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTFwM{e4OVMh|ryP NHf3flJUSU6JRWK=
LS-123 NH:4[4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmKxTWM2OD1zLkO5NFk1KM7:TR?= Mlz3V2FPT0WU
HDLM-2 M4D1O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3r5R2lEPTB;MT6zPVI4OSEQvF2= M4T5O3NCVkeHUh?=
MC-IXC NWLHOYNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljnTWM2OD1zLkSyN|cyKM7:TR?= NGHmcWFUSU6JRWK=
HCT-15 MmfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvSTWM2OD1zLkSzNFY5KM7:TR?= NHvleXRUSU6JRWK=
NCI-H596 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrUTWM2OD1zLkS1NFYyKM7:TR?= MXPTRW5ITVJ?
ZR-75-30 NHW2RWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnZTWM2OD1zLkS3NFgzKM7:TR?= M3LKNHNCVkeHUh?=
A704 MoTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInsVoxKSzVyPUGuOlY2PjNizszN NETVVHJUSU6JRWK=
OVCAR-4 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LUUGlEPTB;MT62PVYxPyEQvF2= MUTTRW5ITVJ?
SW1417 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGixZpBKSzVyPUGuO|I5PDlizszN M{D1cXNCVkeHUh?=
CAS-1 NF7UW|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TKe2lEPTB;MT63N|k{PiEQvF2= MYfTRW5ITVJ?
IST-SL1 NYDVZnpbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4X5OWlEPTB;MT63PVc2QSEQvF2= NVTCXXdRW0GQR1XS
A253 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYH1U4d[UUN3ME2xMlgzOjN7IN88US=> MXLTRW5ITVJ?
EW-16 NWrWZopjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfYb5hKSzVyPUGuPFI5PzVizszN M2fOb3NCVkeHUh?=
SK-NEP-1 NWLqNJFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLoR4tKSzVyPUGuPFY6QDhizszN M4PMUHNCVkeHUh?=
NCI-H226 NILzbVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrITWM2OD1zLki5N|U6KM7:TR?= MWjTRW5ITVJ?
HOP-92 NHrTfZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vEVmlEPTB;MT65OlA6QSEQvF2= NF\aXJBUSU6JRWK=
NCI-H441 Mn7GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTJwMEKzN|ch|ryP MlzrV2FPT0WU
LU-139 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrTflNKSzVyPUKuNFMyOTRizszN NEPYWZBUSU6JRWK=
SJRH30 NEnrbmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\ZVGlEPTB;Mj6wOFI2OyEQvF2= MljzV2FPT0WU
MG-63 NIjjV5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fmXWlEPTB;Mj6xOFEyOSEQvF2= NELhVVlUSU6JRWK=
NH-12 NIntcI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonZTWM2OD1{LkG1NFA3KM7:TR?= NIn3S2dUSU6JRWK=
NB7 Mne4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrJTWM2OD1{LkG5Olc{KM7:TR?= NH3ub4tUSU6JRWK=
LB771-HNC MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTJwMkC1PVUh|ryP MXHTRW5ITVJ?
HCC1569 M2eyPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGK4dJFKSzVyPUKuNlQ2QDNizszN NFn5ZW5USU6JRWK=
D-283MED M4m2ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17HemlEPTB;Mj6yOFc5OiEQvF2= M3LueXNCVkeHUh?=
J-RT3-T3-5 NF7mNoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3vTWM2OD1{LkK1N|UyKM7:TR?= NH3COWFUSU6JRWK=
ATN-1 NUfoV4ZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEP1dYRKSzVyPUKuN|MxQDJizszN MlH0V2FPT0WU
HCC1954 NY\FZ2pUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFntUGlKSzVyPUKuN|Q1ODhizszN M3PoSnNCVkeHUh?=
SCC-15 NUPUZVNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXwe3hKSzVyPUKuN|k{OTJizszN NIfhVpFUSU6JRWK=
COLO-668 M2PPTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDIZ5JKSzVyPUKuOFMzKM7:TR?= M1\iVXNCVkeHUh?=
LB373-MEL-D NInwblRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfkVJJKSzVyPUKuOVQ3PzdizszN MlvzV2FPT0WU
no-10 M4nZeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkK4TWM2OD1{LkW0PVQ4KM7:TR?= NWXFN4NFW0GQR1XS
HT-1197 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;oZWlEPTB;Mj62N|E5QCEQvF2= M1TwNXNCVkeHUh?=
DU-145 MonaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7EU25KSzVyPUKuO|kyPjJizszN NYjrbHhKW0GQR1XS
SK-N-AS MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nMfWlEPTB;Mj64OFY6OiEQvF2= NVLvZWFlW0GQR1XS
MOLT-4 NWXKNZpsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTJwOEWzNlIh|ryP NVjrUlF{W0GQR1XS
EW-22 Mk[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHhOJVKSzVyPUKuPVI5PDFizszN M3HLXnNCVkeHUh?=
DB M36zbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnOXlhYUUN3ME2yMlk4PzV7IN88US=> NUXTcoNyW0GQR1XS
HL-60 M{XUXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTrdYRKSzVyPUOuNFQ{PzZizszN M3nmUXNCVkeHUh?=
SK-N-DZ NEPLcndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLpcGxyUUN3ME2zMlA2ODd3IN88US=> NUTB[|BFW0GQR1XS
NY M1[1b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljHTWM2OD1|LkC4OVQzKM7:TR?= NWO3RoxMW0GQR1XS
T47D NF;UeHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjU[GZqUUN3ME2zMlExPTV6IN88US=> M1:zRXNCVkeHUh?=
NCI-H2029 M3yydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTNwMkK0O|ch|ryP NF7XeYFUSU6JRWK=
KARPAS-299 M135NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTNwMk[wNlch|ryP NUXpdnkzW0GQR1XS
KM-H2 NVz5[ms6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLvfXNKSzVyPUOuN|A3QCEQvF2= MlzWV2FPT0WU
CHP-134 NWDocVh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXwTWM2OD1|LkS3N|kh|ryP MWnTRW5ITVJ?
22RV1 NF\NOHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HyUWlEPTB;Mz60PVE3QCEQvF2= MVLTRW5ITVJ?
NB5 M4PWemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrzTWM2OD1|LkWwOlg6KM7:TR?= MX3TRW5ITVJ?
CW-2 NHnXOVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHf1T|FKSzVyPUOuOVU{OTRizszN MYHTRW5ITVJ?
EFO-21 NIXOUHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoWyTWM2OD1|LkW2PVQh|ryP NX\ifm9OW0GQR1XS
HuH-7 NEDvWZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTKb|RKSzVyPUOuOVg1OTRizszN NHnVV4ZUSU6JRWK=
ALL-PO MkDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PTSGlEPTB;Mz62NlM{PSEQvF2= MYXTRW5ITVJ?
EM-2 NVvGOlh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjpVHVrUUN3ME2zMlY6ODFzIN88US=> MmTGV2FPT0WU
KLE NGDGWoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjld25PUUN3ME2zMlc{ODJ7IN88US=> MYjTRW5ITVJ?
NEC8 NF7wN3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTNwOUG4NFgh|ryP MWnTRW5ITVJ?
KP-N-YN NYrLU5dIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVn3UnloUUN3ME2zMlk{PDd4IN88US=> M1HBWnNCVkeHUh?=
SK-MEL-1 Ml3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzlTWM2OD12LkCzOVE5KM7:TR?= NYfsSlU2W0GQR1XS
CAL-54 M3\temdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrw[G5KSzVyPUSuNFU6OSEQvF2= NFzy[IlUSU6JRWK=
MS-1 M2D2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTRwMU[xOVUh|ryP NFnRO5lUSU6JRWK=
NCI-H209 M1L2VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTXWWpDUUN3ME20MlI6QTl7IN88US=> M4q5NnNCVkeHUh?=
NOMO-1 NEG1dZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmn2TWM2OD12LkOyNVMyKM7:TR?= MnfQV2FPT0WU
RPMI-2650 NHfuZWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXLTWM2OD12LkO2N|I4KM7:TR?= Mk\pV2FPT0WU
NCI-H810 M17xd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTRwM{m3N|Yh|ryP MnzrV2FPT0WU
Ca9-22 NUf1RlRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jHbWlEPTB;ND60OVY6OSEQvF2= NIfO[lNUSU6JRWK=
ES4 NE\LUJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTRwNEewPVUh|ryP NVvXbodRW0GQR1XS
ES6 M4W5fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTRwNEm2OVch|ryP M3;tbnNCVkeHUh?=
DMS-114 M1[5b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTRwNUS2PVEh|ryP NF\2W3dUSU6JRWK=
ONS-76 M2Tudmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoH2TWM2OD12LkW3PVUh|ryP MnOyV2FPT0WU
K-562 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jQTWlEPTB;ND63N|gyPCEQvF2= M2PpdXNCVkeHUh?=
MHH-NB-11 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTRwN{W0OlEh|ryP MYPTRW5ITVJ?
Calu-3 MmjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nIb2lEPTB;ND63PFU1QCEQvF2= MXLTRW5ITVJ?
HT55 MlTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPiTWM2OD12Lki0OVQ2KM7:TR?= NI\MfJBUSU6JRWK=
SK-N-FI NYO1fWVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGX4S3JKSzVyPUSuPFUxODlizszN NFz0UINUSU6JRWK=
ES1 NUXiZnRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vGVWlEPTB;ND64OlA2PyEQvF2= NVroNY5jW0GQR1XS
SF126 NWDTbZk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknSTWM2OD12LkmzNVg1KM7:TR?= MkLhV2FPT0WU
ES5 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHXTWM2OD13LkGyOFI4KM7:TR?= M1H2T3NCVkeHUh?=
LoVo NV[1b3NJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvBUZhKSzVyPUWuNVU5PzFizszN NUTpOWxiW0GQR1XS
SNU-387 M3fCfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTVwM{KzN|kh|ryP MoS5V2FPT0WU
C8166 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XXbmlEPTB;NT6zOlM{QSEQvF2= NH7kU5ZUSU6JRWK=
LS-1034 NX6zU2dKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXMTWM2OD13LkSyN|A4KM7:TR?= NXPFWYFPW0GQR1XS
GR-ST MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTVwNUKyNFEh|ryP MoLKV2FPT0WU
NCI-H1092 M{LZNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjGTWM2OD13LkeyPFQ{KM7:TR?= MlXoV2FPT0WU
647-V M4riNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrsTWM2OD13Lke0O|A3KM7:TR?= NFKyZlBUSU6JRWK=
EW-13 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;RTWM2OD13Lke2OlI4KM7:TR?= NV3hUGpSW0GQR1XS
KGN MkjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnNTItCUUN3ME22MlA6QTJzIN88US=> NGPBS3dUSU6JRWK=
D-423MG MmHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPj[odKSzVyPU[uOFAzQDRizszN NVXBVpVwW0GQR1XS
ECC10 NEPtcJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PlfWlEPTB;Nz6xNFExOSEQvF2= M13DNHNCVkeHUh?=
TE-5 NWTZ[JFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXPSWlKSzVyPUeuOFEzQThizszN MVnTRW5ITVJ?
P12-ICHIKAWA NGm2eHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTdwNEW1NlMh|ryP MkfRV2FPT0WU
NCI-H82 M3LRR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;ZbnJTUUN3ME23MlQ2PzBzIN88US=> MUfTRW5ITVJ?
NCI-H1993 Mne1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTdwOEOwOlMh|ryP NFHTUFVUSU6JRWK=
RH-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPPO|dKSzVyPUeuPFUzPDRizszN M2\aR3NCVkeHUh?=
SW948 NWXRNJZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrLeWFFUUN3ME23Mlk3ODR7IN88US=> M3vBb3NCVkeHUh?=
CAL-33 NFTvV4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnCemZlUUN3ME23Mlk6QTN6IN88US=> NGDYNo5USU6JRWK=
U-266 NX23Z4FRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrUfJBKSzVyPUiuNVU4PzdizszN NXfQfXU5W0GQR1XS
CAL-72 NEW3T3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLjTWM2OD16LkKwN|Ih|ryP MV\TRW5ITVJ?
SNU-423 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXPTWM2OD17LkO2OlY3KM7:TR?= MnjXV2FPT0WU
KG-1 MmDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{[zXmlEPTB;OT61PFQ2PiEQvF2= Mn7TV2FPT0WU
HCC1395 NHLRSYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3j2eGlEPTB;OT65NlM2OiEQvF2= MnqzV2FPT0WU
BE-13 M3WwcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLM[lI3UUN3ME2xNE45QDl{IN88US=> MnLSV2FPT0WU
MKN7 NUHw[HBDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;qW|lKSzVyPUGwMlk4PjVizszN NFuwdXlUSU6JRWK=
697 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEH3cm1KSzVyPUGxMlE1PzJizszN M4LEbXNCVkeHUh?=
LU-135 NFPRfZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PYVmlEPTB;MUGuNlMxPyEQvF2= NHrhe41USU6JRWK=
ES7 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVn0cJZEUUN3ME2xNU4{OzF|IN88US=> MV7TRW5ITVJ?
SK-HEP-1 NYHXVmV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\CTWM2OD1zMT63OlQ3KM7:TR?= NIq0XmxUSU6JRWK=
BEN MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTFzLki1NUDPxE1? M3rDNXNCVkeHUh?=
NCI-H1770 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2foU2lEPTB;MUKuNVI3KM7:TR?= NWjDdZVLW0GQR1XS
SW13 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYq5VG9{UUN3ME2xNk4yPTRzIN88US=> MljKV2FPT0WU
MZ1-PC M3LFfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjJXmtGUUN3ME2xNk42PDV{IN88US=> NInNelhUSU6JRWK=
Mo-T NXPZWJpKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTF{Lke0NlEh|ryP MXjTRW5ITVJ?
HLE NEnLOolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nZWWlEPTB;MUKuPFIyPSEQvF2= NYC3NnA3W0GQR1XS
RCC10RGB NEH4ZodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PNVmlEPTB;MUOuOlcyKM7:TR?= Moj5V2FPT0WU
COLO-320-HSR M1TaUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTF|LkezPFEh|ryP MlrDV2FPT0WU
BHT-101 MlHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoWzTWM2OD1zMz64N|Q2KM7:TR?= Mn;NV2FPT0WU
OCUB-M NGXHdJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVr2SXVxUUN3ME2xOE4yPjB{IN88US=> NFrhRoxUSU6JRWK=
MEG-01 MlfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHy2cXdKSzVyPUG0MlM4ODhizszN MYPTRW5ITVJ?
RS4-11 M1noW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnGe3h{UUN3ME2xOE44PDJizszN MmCxV2FPT0WU
MN-60 NXHsUHpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkT5TWM2OD1zND63PFk1KM7:TR?= MmXMV2FPT0WU
NCI-H1304 NIXIeplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M365UGlEPTB;MUWuNFQzPSEQvF2= NXq0R4dnW0GQR1XS
Ramos-2G6-4C10 M1XaeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\pTWM2OD1zNT6wOVgyKM7:TR?= NUTLZno2W0GQR1XS
NCI-H2342 NHjBSoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTF3LkKwOFQh|ryP NGX3S29USU6JRWK=
LAN-6 NVrsd2dMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfvTWM2OD1zNT60OFE1KM7:TR?= M33FZnNCVkeHUh?=
JVM-2 NXHQVotpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml21TWM2OD1zNT61O|Q5KM7:TR?= NWHzW5hzW0GQR1XS
P30-OHK NU\FN5BrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mly2TWM2OD1zNj6wOlE1KM7:TR?= MVfTRW5ITVJ?
C-33-A MkTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPpTWM2OD1zNj62NlE1KM7:TR?= MlLyV2FPT0WU
RPMI-8866 MmLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTF4Lki0PVYh|ryP M{XjdXNCVkeHUh?=
NCI-H630 NX3KVllYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTF4Lki1N|ch|ryP NVfBWXo5W0GQR1XS
KYSE-140 NIXodYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTF5LkKwNlgh|ryP MoPzV2FPT0WU
T84 NGPE[mdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmizTWM2OD1zOD64Olk2KM7:TR?= M2rHTHNCVkeHUh?=
KU-19-19 MnOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnflTWM2OD1zOD65OlA5KM7:TR?= MXrTRW5ITVJ?
BALL-1 M4rKTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPyTWM2OD1zOT6zN|k6KM7:TR?= NFLsbZRUSU6JRWK=
Calu-6 NV;YTJRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELtZmdKSzVyPUG5MlQ6OiEQvF2= NF3YXldUSU6JRWK=
EGI-1 NFfIdGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTF7LkW5PEDPxE1? NGfIRoVUSU6JRWK=
MFH-ino M4nKPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DLc2lEPTB;MUmuO|Q2PCEQvF2= MXXTRW5ITVJ?
GB-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTJyLkO1N|Uh|ryP NF;1OnNUSU6JRWK=
NCI-H1693 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTJyLk[1NFUh|ryP MmWxV2FPT0WU
SW1116 NVT4cW01T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLDdGNxUUN3ME2yNE46OzZ{IN88US=> MUXTRW5ITVJ?
H-EMC-SS M{LRbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2foRWlEPTB;MkKuNFQ2KM7:TR?= MVHTRW5ITVJ?
D-502MG Mof0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3y5PWlEPTB;MkKuPFI3OSEQvF2= M4XIVXNCVkeHUh?=
IA-LM MoG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULMfFF6UUN3ME2yN{4zPDl|IN88US=> MXLTRW5ITVJ?
SW1463 M33oZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTJ|Lke5JO69VQ>? NFXWNINUSU6JRWK=
JAR MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17PdGlEPTB;MkSuN|I6OyEQvF2= MX;TRW5ITVJ?
HT MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XlWWlEPTB;MkSuOFc2OyEQvF2= MUHTRW5ITVJ?
LCLC-103H M{W5e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoGwTWM2OD1{ND64OFQ6KM7:TR?= MVLTRW5ITVJ?
SNU-449 NWrQdmYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PQTGlEPTB;MkSuPFc1OSEQvF2= MnfsV2FPT0WU
KE-37 MmOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;3[mlEPTB;MkWuNFkzQCEQvF2= MVPTRW5ITVJ?
NCI-H1623 M{jG[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTJ5LkGzNFMh|ryP M1G3e3NCVkeHUh?=
MOLT-13 NIL5bndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTJ5LkO1NVYh|ryP NIXZRY9USU6JRWK=
COLO-741 NFrO[ZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTNzLkOzN|Mh|ryP NETFWoZUSU6JRWK=
NB6 M1HZ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3rNWRKSzVyPUOyMlI5PzZizszN MUXTRW5ITVJ?
MOLT-16 NIHwb5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnm0TWM2OD1|Mz6wNFU2KM7:TR?= M4D4O3NCVkeHUh?=
IST-MES1 Ml3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2P3dGlEPTB;M{SuNFU1OSEQvF2= NVHPPYZsW0GQR1XS
A4-Fuk NUj1RYVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTyeGNKSzVyPUO1MlA3PiEQvF2= NFfKd|JUSU6JRWK=
CAL-85-1 NGS2cW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlm3TWM2OD1|NT6yPFE4KM7:TR?= MWLTRW5ITVJ?
CCRF-CEM NUPJWXV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnGUppKSzVyPUO3MlE2OzZizszN NGPwZZpUSU6JRWK=
HAL-01 MkKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDifoRKSzVyPUO4MlQ5QDlizszN NFvCTnJUSU6JRWK=
HEL MlvES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mny2TWM2OD12Mz6zOFA6KM7:TR?= M{HZfXNCVkeHUh?=
EW-1 NX3xZZR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzaTWM2OD12Mz60O|Y5KM7:TR?= MYjTRW5ITVJ?
MDA-MB-231 NIT2c3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITodoFKSzVyPUS1MlEyQTlizszN NHm4V4pUSU6JRWK=
ABC-1 M{HMRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjHcVBIUUN3ME20Ok45PTN6IN88US=> NX;hSWdyW0GQR1XS
NCI-H446 MmrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPzU|lKSzVyPUS4MlUxPThizszN NFLJeWNUSU6JRWK=
MHH-PREB-1 NWnC[VRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjtTWM2OD12OT62NFA4KM7:TR?= NVX3So81W0GQR1XS
DOHH-2 MnTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzZTWM2OD12OT62OlU3KM7:TR?= NGPqfVBUSU6JRWK=
GCT M{HGRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF[4WGhKSzVyPUS5MlY6PzZizszN M1e5bXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
α-Synuclein / HSP90 / HSP70 / HSP32 / αB-Crystallin; 

PubMed: 20090920     


Immunoblot analysis of heat shock protein induction. Cells were treated with 17-AAG (1–200 nM, 24 h), or subjected to heat shock (HS: 44°C, 30 min, 24 h recovery) or to MG-132 (MG: 1 µM, 24 h). Cell lysates were prepared and immunoblot analysis was carried out with antibodies against the individual proteins as indicated on the right. Co, untreated control.

EGFR / PDGFR / AKT / MAPK / c-RAS; 

PubMed: 18682579     


17-AAG promotes the degradation of HSP90 client proteins that are involved in the pathology of glioblastoma multiforme (GBM). Glioma cell lines were treated with increasing concentrations of 17-AAG for 48 h, and protein lysates were run on Western blots. HSP90 client proteins known to be involved in gliomagenesis showed degradation while nonclient proteins remained unaffected by 17-AAG treatment.

pAKT / pMAPK / pRb; 

PubMed: 18682579     


The phosphorylated states of signaling proteins involved in glioma growth are also affected by 17-AAG treatment.

Cleaved PARP / Survivin; 

PubMed: 18827603     


Western analysis of expression levels of cleaved PARP and Survivin in MM cell lines. β-Actin served as loading control.

LATS1 / p-LATS1 / YAP / CTGF; 

PubMed: 25712415     


Effects of 17-AAG on the expression of LATS1, p-LATS1, YAP and CTGF.  The expression levels of YAP and CTGF proteins, indicated by Western blot assay, were down-regulated, while LATS1 was upregulated in a dose-dependent manner in 17-AAG treated groups compared to the untreated group.

20090920 18682579 18827603 25712415
Immunofluorescence
STAT3; 

PubMed: 27279418     


Effects of 17-AAG on STAT3 expression of H446 cells. (A) Control group; (B) 3.125 mg/l; (C) 6.25 mg/l. 17-AAG, 17-allylamino-17-demethoxygel-danamycin; STAT3, signal transducer and activator of transcription 3; DAPI, 4′,6-diamidino-2-phenylindole.

YAP / TAZ; 

PubMed: 25290150     


Reduction in cytoplasmic distribution accompanied by increased nuclear localization of YAP/TAZ was more apparent in cells treated with 45 nM 17-AAG (red channel for YAP/TAZ and blue channel for nucleus). Statistical comparisons were performed using one-way Kruskal-Wallis multiple comparison, ***p<0.001 compared with control (0 nM).

β-catenin / E-cadherin; 

PubMed: 25290150     


Co-localization of β-catenin (Red) and E-cadherin (Green) was observed at the cell-cell junctions (white arrows) both in siCtrl and siCTGF cells after 17-AAG treatment. Scale bar is 20 µm.

27279418 25290150
Growth inhibition assay
Cell viability; 

PubMed: 18682579     


17-AAG inhibits the growth of human glioma cell lines. Human glioma cell lines and a nontumorigenic fibroblast cell line were treated with increasing concentrations of 17-AAG for 4 days, and the effect on cell growth was assessed by a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) assay. The 50% inhibitory concentration (IC50) of all glioma cell lines ranged from 0.05 to 0.5 μM 17-AAG, as compared to 1.5 μM for the nontumorigenic cells.

18682579
In vivo 17-AAG displays significantly higher binding affinity for Hsp90 from 3T3-src, B16 or CT26 xenografts in nude mice with IC50 values of 8-35 nM as compared with that from the normal tissues with IC50 values of 200-600 nM. [1] Administration of 17-AAG (~50 mg/kg) causes significant decline in AR, HER2, HER3, and Akt expression in a dose-dependent manner with >50% decline at dose of 50 mg/kg, resulting in the dose-dependent inhibition of androgen-dependent (CWR22) and -independent (CWR22R and CWRSA6) prostate cancer xenografts growth by 67%, 80% and 68% at dose of 50 mg/kg, respectively. [2]

Protocol

Kinase Assay:[1]
- Collapse

Hsp90 binding assays:

Purified native Hsp90 protein or cell lysates from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells in lysis buffer (20 mM HEPES, pH 7.3, 1 mM EDTA, 5 mM MgCl2, 100 mM KCl) are incubated with various concentrations of 17-AAG for 30 minutes at 4 °C, and then incubated with biotin-GM linked to BioMag streptavidin magnetic beads for 1 hour at 4 °C. Tubes are placed on a magnetic rack, and the unbound supernatant removed. The magnetic beads are washed three times in lysis buffer and heated for 5 minutes at 95 °C in SDS–PAGE sample buffer. Samples are analysed on SDS protein gels, and western blots done using indicated antibodies. Bands in the western blots are quantified using the Bio-rad Fluor-S MultiImager, and the percentage inhibition of binding of Hsp90 to the biotin-GM is calculated. The IC50 reported is the concentration of 17-AAG needed to cause half-maximal inhibition of binding.
Cell Research:[1]
- Collapse
  • Cell lines: BT474, SKBR3, N87, SKOV3, MCF7, MDA468, Hs578T, Hs578Bst, A549, HT29, U87, SKMG3, HT1080, RPTEC, NDF, HMVEC, HMEC, HUVEC, and PBMC cells
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 5 days
  • Method: Cells are seeded in 96-well plates at 2,000 cells per well in a final culture volume of 100 μL for 24 hours before the addition of increasing concentrations of 17-AAG that is incubated for 5 days. Viable cell number is determined using the Celltiter 96 AQueous Nonradioactive Cell Proliferation Assay. The value of the background absorbance at 490 nm (A490) of wells not containing cells is subtracted. Percentage of viable cells = (A490 of 17-AAG treated sample/A490 untreated cells) × 100. The IC50 is defined as the concentration that gave rise to 50% viable cell number.
    (Only for Reference)
Animal Research:[2]
- Collapse
  • Animal Models: Male nu/nu athymic mice inoculated s.c. with androgen-dependent CWR22 xenograft, and female nu/nu athymic mice inoculated s.c. with androgen-independent xenografts CWR22R and CWRSA6
  • Dosages: ~50 mg/kg
  • Administration: Injection i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (170.73 mM)
Water Insoluble
Ethanol '5 mg/mL
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5%DMSO+corn oil
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 585.69
Formula

C31H43N3O8

CAS No. 75747-14-7
Storage powder
in solvent
Synonyms CP127374,NSC-330507, KOS 953
Smiles CC1CC(C(C(C=C(C(C(C=CC=C(C(=O)NC2=CC(=O)C(=C(C1)C2=O)NCC=C)C)OC)OC(=O)N)C)C)O)OC

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT00103272 Terminated Drug: tanespimycin|Drug: bortezomib Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Waldenström Macroglobulinemia National Cancer Institute (NCI) April 2005 Phase 1
NCT00098488 Terminated Drug: tanespimycin|Biological: rituximab B-cell Chronic Lymphocytic Leukemia|Prolymphocytic Leukemia|Refractory Chronic Lymphocytic Leukemia National Cancer Institute (NCI) April 2005 Phase 1
NCT00118248 Completed Drug: tanespimycin Recurrent Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer|Thyroid Gland Medullary Carcinoma National Cancer Institute (NCI) December 2004 Phase 2
NCT00098423 Completed Drug: tanespimycin|Drug: cytarabine Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Blastic Phase Chronic Myelogenous Leukemia|Chronic Myelomonocytic Leukemia|de Novo Myelodysplastic Syndromes|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Refractory Anemia With Excess Blasts in Transformation|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes National Cancer Institute (NCI) November 2004 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What kind of subtypes does this compound inhibit? HSP90α or HSP90β ?

  • Answer:

    17-AAG can inhibit both HSP90α and HSP90β, but it is unclear how much are they affected respectively. You should note that Hsp90 derived from tumor cells has a 100-fold higher binding affinity for 17-AAG than that from normal cells according to this paper. http://www.nature.com.ezp-prod1.hul.harvard.edu/nature/journal/v425/n6956/full/nature01913.html

HSP (HSP90) Signaling Pathway Map

HSP (HSP90) Inhibitors with Unique Features

Related HSP (HSP90) Products

Tags: buy Tanespimycin (17-AAG) | Tanespimycin (17-AAG) supplier | purchase Tanespimycin (17-AAG) | Tanespimycin (17-AAG) cost | Tanespimycin (17-AAG) manufacturer | order Tanespimycin (17-AAG) | Tanespimycin (17-AAG) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID